KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other financing activities: 2020-2022

Historic Other financing activities for Halozyme Therapeutics (HALO) over the last 1 years, with Dec 2022 value amounting to $639,000.

  • Halozyme Therapeutics' Other financing activities was N/A to $639,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $7.2 million, marking a year-over-year change of. This contributed to the annual value of $7.1 million for FY2022, which is 1575.47% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Other financing activities stood at $639,000 for Q4 2022, which was up 38.31% from $462,000 recorded in Q3 2022.
  • In the past 5 years, Halozyme Therapeutics' Other financing activities ranged from a high of $6.0 million in Q2 2022 and a low of -$68,000 during Q2 2020.
  • Over the past 3 years, Halozyme Therapeutics' median Other financing activities value was $329,000 (recorded in 2021), while the average stood at $1.1 million.
  • Data for Halozyme Therapeutics' Other financing activities shows a peak YoY spiked of 6,218.95% (in 2022) over the last 5 years.
  • Over the past 3 years, Halozyme Therapeutics' Other financing activities (Quarterly) stood at -$68,000 in 2020, then soared by 239.71% to $95,000 in 2021, then soared by 6,218.95% to $639,000 in 2022.
  • Its Other financing activities was $639,000 in Q4 2022, compared to $462,000 in Q3 2022 and $6.0 million in Q2 2022.